Autoimmune uveitis: The associated proinflammatory molecules and the search for immunoregulation

Autoimmunity Reviews

Volumn 10, Issue 4, 2011, Pages 205-209

  Commodaro, Alessandra Goncalves ^a,b   Bueno, Valquiria ^b   Belfort, Rubens ^b   Rizzo, Luiz Vicente ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Autoimmune uveitis; EAU; Immune response; Immunoregulation; Inflammatory molecules

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADALIMUMAB; CYTOKINE; EMBREL; ESBA 105; ETANERCEPT; FINGOLIMOD; GALECTIN 1; GAMMA INTERFERON; GLATIRAMER; HEAT SHOCK PROTEIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEVINOLIN; MONOCLONAL ANTIBODY; OSTEOPONTIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETINOIC ACID; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; VOCLOSPORIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNE UVEITIS; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; EXPERIMENTAL INFLAMMATORY UVEITIS; HUMAN; IMMUNOREGULATION; LENS INDUCED UVEITIS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; UVEITIS; VISUAL IMPAIRMENT;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INFLAMMATION MEDIATORS; PROPYLENE GLYCOLS; SPHINGOSINE; UVEITIS;

EID: 79951849568     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.10.002     Document Type: Review

References (80)

1. Whitcup S.M., Nussenblatt R.B. Immunologic mechanisms of uveitis. New targets for immunomodulation. Arch Ophthalmol 1997, 115:520-525.
2. Jabs D.A., Nussenblatt R.B. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005, 140:509-516.
3. Ehrenfeld M. Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 2010, 9:A325-A329.
4. Punzi L., Furlan A., Podswiadek M., Gava A., Valente M., De Marchi M., et al. Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review. Autoimmun Rev 2009, 8:228-232.
5. Rosenbaum J.T., McDevitt H.O., Guss R.B., Egbert P.R. Endotoxininduced uveitis in rats as a model for human disease. Nature 1980, 286:611-613.
6. Okumura A., Mochizuki M., Nishi M., Herbort C.P. Endotoxininduced uveitis (EIU) in the rat: a study of inflammatory and immunological mechanisms. Int Ophthalmol 1990, 14:31-36.
7. Rao N.A., Bowe B.E., Sevenian A., Till G.O., GEJr Marak Modulation of lens-induced uveitis by dimethyl sulfoxide. Ophthalmic Res 1986, 18:193-198.
8. Koch F.H., Augustin A.J., Grus F.H., Spitznas M.N. Effects of different antioxidants on lensinduced uveitis. Ger J Ophthalmol 1996, 5:185-188.
9. Broekhuyse R.M., Kuhlmann E.D. Experimental autoimmune anterior uveitis. The preparation of uveitogenic ocular melanin. Investig Ophthalmol Vis Sci 1993, 34:698-700.
10. Bora N.S., Woon M.D., Tandhasetti M.T., Cirrito T.P., Kaplan H.J. Induction of experimental autoimmune anterior uveitis by a self-antigen: melanin complex without adjuvant. Investig Ophthalmol Vis Sci 1997, 38:2171-2175.
11. Caspi R.R., Roberge F.G., Chan C.C., Wiggert B., Chader G.J., Rozenszajn L.A., et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988, 140:1490-1495.
12. Nussenblatt R.B., Rodrigues M.M., Wacker W.B., Cevario S.J., Salinas-Carmona M.C., Gery I. Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest 1981, 67:1228-1231.
13. Hamada M., Ogura Y., Miyamoto K., Nishiwaki H., Hiroshiba N., Honda Y. Retinal leukocyte behavior in experimental autoimmune uveoretinitis of rats. Exp Eye Res 1997, 65:445-450.
14. Gery I., Chanaud N.P., Anglade E. Recoverin is highly uveitogenic in Lewis rats. Investig Ophthalmol Vis Sci 1994, 35:3342-3345.
15. Adamus G., Schmied J.L., Hargrave P.A., Arendt A., Moticka E.J. Induction of experimental autoimmune uveitis with rhodopsin synthetic peptides in Lewis rats. Curr Exp Res 1992, 11:657-667.
16. Schalken J.J., Winkens H.J., Van Vugt A.H., De Grip W.J., Broekhuyse R.M. Rhodopsin-induced experimental autoimmune uveoretinitis in monkeys. Br J Ophthalmol 1989, 73:168-172.
17. Chan C.C., Caspi R.R., Ni M., Leake W.C., Wiggert B., Chader G.J., et al. Pathology of experimental autoimmune uveoretinitis in mice. J Autoimmun 1990, 3:247-255.
18. Caspi R.R., Chan C.C., Wiggert B., Chader G.J. The mouse as a model of experimental autoimmune uveoretinitis (EAU). Curr Eye Res 1990, Suppl 9:169-174.
19. Jiang H.R., Lumsden L., Forrester J.V. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10.RIII mice. Investig Ophthalmol Vis Sci 1999, 40:3177-3185.
20. Takeuchi M., Yokoi H., Tsukahara R., Sakai J., Usui M. Differentiation of Th1 and Th2 cells in lymph nodes and spleens of mice during experimental autoimmune uveoretinitis. Jpn J Ophthalmol 2001, 45:463-469.
21. Grajewski R.S., Silver P.B., Agarwal R.K., Su S.B., Chan C.C., Liou G.I., et al. Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunity. J Exp Med 2006, 203:851-856.
22. Keino H., Takeuchi M., Usui Y., Hattori T., Yamakawa N., Kezuka T., et al. Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis. Br J Ophthalmol 2007, 91:105-110.
23. Caspi R.R., Kuwabara T., Nussenblatt R.B. Characterization of a suppressor cell line which downgrades experimental autoimmune uveoretinitis in the rat. J Immunol 1988, 140:2579-2584.
24. Sun M., Yang P., Du L., Zhou H., Ren X., Kijlstra A. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis. Investig Ophthalmol Vis Sci 2010, 51:383-389.
25. Chen L., Yang P., Zhou H., He H., Ren X., Chi W., et al. Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome. Investig Ophthalmol Vis Sci 2008, 49:3475-3482.
26. Mendoza-Pinto C., García-Carrasco M., Jiménez-Hernández M., Jiménez Hernández C., Riebeling-Navarro C., Nava Zavala A., et al. Etiopathogenesis of Behcet's disease. Autoimmun Rev 2010, 9:241-245.
27. Hamzaoui K., Hamzaoui A., Houman H. CD4+CD25+ regulatory T cells in patients with Behçet's disease. Clin Exp Rheumatol 2006, 24(5 Suppl 42):S71-S78.
28. Ling E., Shubinsky G., Press J. Increased proportion of CD3+CD4-CD8- double-negative T cells in peripheral blood of children with Behcet's disease. Autoimmun Rev 2007, 6:237-240.
29. Yoshimura T., Sonoda K.H., Miyazaki Y., Iwakura Y., Ishibashi T., Yoshimura A., et al. Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int Immunol 2008, 20:209-214.
30. Liu L., Xu Y., Wang J., Li H. Upregulated IL-21 and IL-21 receptor expression is involved in experimental autoimmune uveitis (EAU). Mol Vis 2009, 15:2938-2944.
31. Akdeniz N., Esrefoglu M., KeleŞ M.S., Karakuzu A., Atasoy M. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Ann Acad Med Singapore 2004, 33:596-599.
32. Chi W., Zhu X., Yang P., Liu X., Lin X., Zhou H., et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Investig Ophthalmol Vis Sci 2008, 49:3058-3064.
33. Chi W., Yang P., Li B., Wu C., Jin H., Zhu X., et al. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 2007, 119:1218-1224.
34. Commodaro A.G., Peron J.P., Genre J., Arslanian C., Sanches L., Muccioli C., et al. IL-10 and TGF-beta immunoregulatory cytokines rather than natural regulatory T cells are associated with the resolution phase of Vogt-Koyanagi-Harada (VKH) syndrome. Scand J Immunol 2010, 72:31-37.
35. Hikita S.T., Vistica B.P., Jones H.R., Keswani J.R., Watson M.M., Ericson V.R., et al. Osteopontin is proinflammatory in experimental autoimmune uveitis. Investig Ophthalmol Vis Sci 2006, 47:4435-4443.
36. Kitamura M., Iwabuchi K., Kitaichi N., Kon S., Kitamei H., Namba K., et al. Osteopontin aggravates experimental autoimmune uveoretinitis in mice. J Immunol 2007, 178:6567-6572.
37. Zhang M., Chan C.C., Vistica B., Hung V., Wiggert B., Gery I. Copolymer 1 inhibits experimental autoimmune uveoretinitis. J Neuroimmunol 2000, 103:189-194.
38. Gegg M.E., Harry R., Hankey D., Zambarakji H., Pryce G., Baker D., et al. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J Immunol 2005, 174:2327-2335.
39. Cunningham M.A., Austin B.A., Li Z., Liu B., Yeh S., Chan C.C., et al. LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells. Investig Ophthalmol Vis Sci 2009, 50:249-255.
40. Keino H., Watanabe T., Sato Y., Okada A.A. Anti-inflammatory effect of retinoic acid on experimental autoimmune uveoretinitis. Br J Ophthalmol 2010, 94:802-807.
41. Whitcup S.M., DeBarge L.R., Caspi R.R., Harning R., Nussenblatt R.B., Chan C.C. Monoclonal. antibodies against ICAM-1 (CD54) and LFA-1 (CD11c/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol 1993, 67:143-150.
42. Devine L., Lightman S.L., Greenwood J. Role of LFA-1, ICAM-1, VLA-4 and VCAM-1 in lymphocyte migration across retinal pigment epithelial monolayers in vitro. Immunology 1996, 88:456-462.
43. Martín A.P., de Moraes L.V., Tadokoro C.E., Commodaro A.G., Urrets-Zavalia E., Rabinovich G.A., et al. Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis. Investig Ophthalmol Vis Sci 2005, 46:2056-2063.
44. Liu F.T. Regulatory roles of galectins in the immune response. Int Arch Allergy Immunol 2005, 146:385-400.
45. Toscano M.A., Commodaro A.G., Ilarregui J.M., Bianco G.A., Liberman A., Serra H.M., et al. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J Immunol 2006, 176:6323-6332.
46. Su S.B., Silver P.B., Wang P., Chan C.C., Caspi R.R. Cholera toxin prevents Th1-mediated autoimmune disease by inducing immune deviation. J Immunol 2004, 173:755-761.
47. Stanford M.R., Kasp E., Whiston R., Hasan A., Todryk S., Shinnick T., et al. Heat shock protein peptides reactive in patients with Behçet's disease are uveitogenic in Lewis rats. Clin Exp Immunol 1994, 97:226-231.
48. Pervin K., Childerstone A., Shinnick T., Mizushima Y., van der Zee R., Hasan A., et al. T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behçet's disease. J Immunol 1993, 151:2273-2282.
49. Direskeneli H., Hasan A., Shinnick T., Mizushima R., van der Zee R., Fortune F., et al. Recognition of B-cell epitopes of the 65kDa HSP in Behçet's disease. Scand J Immunol 1996, 43:464-471.
50. Marengo E.B., Commodaro A.G., Peron J.P., de Moraes L.V., Portaro F.C., Belfort R., et al. Administration of Mycobacterium leprae rHsp65 aggravates experimental autoimmune uveitis in mice. PLoS ONE 2009, 4:e7912.
51. Commodaro A.G., Bombardieri C.R., Peron J.P., Saito K.C., Guedes P.M., Hamassaki D.E., et al. p38{alpha} MAP kinase controls IL-17 synthesis in Vogt-Koyanagi-Harada syndrome and experimental autoimmune uveitis. Investig Ophthalmol Vis Sci 2010, 51:3567-3574.
52. Sonoda K.H., Yoshimura T., Takeda A., Ishibashi T., Hamano S., Yoshida H. WSX-1 plays a significant role for the initiation of experimental autoimmune uveitis. Int Immunol 2007, 19:93-98.
53. Hohki S., Ohguro N., Haruta H., Nakai K., Terabe F., Serada S., et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res 2010, 91:162-170.
54. Szekanecz Z., Szántó S., Szabó Z., Váncsa A., Szamosi S., Bodnár N., et al. Biologics - beyond the joints. Autoimmun Rev 2010, 9:820-824.
55. Lim W.K., Fujimoto C., Ursea R., Mahesh S.P., Silver P., Chan C.C., et al. Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol 2005, 123:957-963.
56. Zhang R., Qian J., Guo J., Yuan Y.F., Xue K. Suppression of experimental autoimmune uveoretinitis by anti-IL-17 antibody. Curr Eye Res 2009, 34:297-303.
57. Okada A.A., Sakai J., Usui M., Mizuguchi J. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998, 6:111-120.
58. Nakamura S., Yamakawa T., Sugita M., Kijima M., Ishioka M., Tanaka S., et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Investig Ophthalmol Vis Sci 1994, 35:3884-3889.
59. Sartani G., Silver P.B., Rizzo L.V., Chan C.C., Wiggert B., Mastorakos G., et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Investig Ophthalmol Vis Sci 1996, 37:2211-2218.
60. Robertson M., Liversidge J., Forrester J.V., Dick A.D. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Investig Ophthalmol Vis Sci 2003, 44:3034-3041.
61. Ramos-Casals M., Roberto-Perez-Alvarez, Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010, 9:188-193. BIOGEAS Study Group.
62. Simonini G., Cantarini L., Bresci C., Lorusso M., Galeazzi M., Cimaz R. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 2010, 9:674-683.
63. Saurenmann R.K., Levin A.V., Rose J.B., Parker S., Rabinovitch T., Tyrrell P.N., et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006, 45:982-989. (Oxford).
64. Valesini G., Iannuccelli C., Marocchi E., Pascoli L., Scalzi V., Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007, 7:35-41.
65. Reiff A., Takei S., Sadeghi S., Stout A., Shaham B., Bernstein B., et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001, 44:1411-1415.
66. Fonollosa A., Segura A., Giralt J., Garcia-Arumi J. Tuberculous uveitis after treatment with etanercept. Graefes Arch Clin Exp Ophthalmol 2007, 245:1397-1399.
67. Tauber T., Turetz J., Barash J., Avni I., Morad Y. Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS 2006, 10:26-29.
68. Hosseini H., Safaei A., Khalili M.R., Nowroozizadeh B., Eghtedari M., Farvardin M., et al. Intravitreal infliximab in experimental endotoxin-induced uveitis. Eur J Ophthalmol 2009, 19:818-823.
69. Tynjälä P., Lindahl P., Honkanen V., Lahdenne P., Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007, 66:548-550.
70. Saurenmann R.K., Levin A.V., Feldman B.M., Laxer R.M., Schneider R., Silverman E.D. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006, 149:833-836.
71. Galor A., Perez V.L., Hammel J.P., Lowder C.Y. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006, 113:2317-2323.
72. Biester S., Deuter C., Michels H., Haefner R., Kuemmerle-Deschner J., Doycheva D., et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007, 91:319-324.
73. Ottiger M., Thiel M.A., Feige U., Lichtlen P., Urech D.M. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Investig Ophthalmol Vis Sci 2009, 50:779-786.
74. Furrer E., Berdugo M., Stella C., Behar-Cohen F., Gurny R., Feige U., et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Investig Ophthalmol Vis Sci 2009, 50:771-778.
75. Yanagawa Y., Masbuchi Y., Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing. Immunology 1998, 95:591-594.
76. Schwab S.R., Cyster J.G. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007, 8:1295-1301.
77. Sakaguchi M., Sugita S., Sagawa K., Itoh K., Mochizuki M. Cytokine production by T cells infiltrating in the eye of uveitis patientS. Jpn J Ophthalmol 1998, 42:262-268.
78. Kurose S., Ikeda E., Tokiwa M., Hikita N., Mochizuki M. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp Eye Res 2000, 70:7-15.
79. Raveney B.J.E., Copland D.A., Nicholson L.B., Dick A.D. Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease. Arch Ophthalmol 2008, 126:1390-1395.
80. Commodaro A.G., Peron J.P., Lopes C.T., Arslanian C., Belfort R., Rizzo L.V., et al. Evaluation of experimental autoimmune uveitis in mice treated with FTY720. Investig Ophthalmol Vis Sci 2010, 51:2568-2574.